Goodall et al. [39] showed that vemurafenib effectively blocked oncogenic BRAF signaling, as shown by reduced phosphorylation of the downstream effector, ERK1/2, with no effect on the autophagic flux, as indicated by unchanged levels of LC3II in A375 melanoma cells. Here, BRAF is linked to melanoma.